Market Dashboard

Snapshot View

Interactive Charts

Latest Market Commentary

Market Commentary | March 30th, 2026

Mar 30, 2026

It was a short and relatively light week for economic data, but the releases still provided a useful snapshot of the economy.

Market Commentary | March 23rd, 2026

Mar 23, 2026

The U.S./Israel conflict with Iran has continued to cause significant volatility within markets, and given this, we felt it was important to provide an additional update.

Market Commentary | March 16th, 2026

Mar 16, 2026

Last week delivered a concentrated set of U.S. economic data that helped refine expectations around growth, inflation, and the Federal Reserve’s policy path. While housing data showed tentative improvement, inflation measures and revised growth figures reinforced a cautious macro backdrop.

Market Commentary | March 9th, 2026

Mar 9, 2026

Last week delivered many important macroeconomic releases, giving investors insight into an evolving U.S. economic landscape. In addition, the conflict in Iran has escalated dramatically, adding significant economic concerns.

« Older Entries

Next Entries »

Latest Market News from Around the Web

Personal Finance

General Motors is set to report earnings before the bell. Here's what Wall Street expects
April 27, 2026
Aside from earnings and any change to GM's 2026 guidance, investors are monitoring impact from the Iran war, tariffs and EV write-downs.
Domino's Pizza stock falls on disappointing sales — and CEO thinks more chains will follow
April 27, 2026
CEO Russell Weiner said he expects more fast-food chains will report that winter weather and weak consumer sentiment hurt their quarterly sales.
Pharma bets a little-known form of cholesterol will underpin its next blockbuster heart drugs
April 27, 2026
Novartis, Amgen and Eli Lilly are betting that slashing levels of a particularly bad form of cholesterol could deliver the next blockbusters in cardiology.
Intellia Therapeutics says its Crispr-based treatment succeeds in pivotal trial
April 27, 2026
Intellia Therapeutics said its Crispr-based treatment for hereditary angioedema met its goals in a Phase 3 trial, marking a milestone for gene editing.

Investment

Tuesday's big stock stories: What’s likely to move the market in the next trading session
April 27, 2026
The S&P 500 rose to a fresh all-time high and closing record on Monday as traders looked past gridlocked peace talks between the U.S. and Iran.
Saba Capital finds little appetite for tender offer of shares in Blue Owl, Starwood private credit funds
April 27, 2026
Investors' disinterest in getting liquidity at a steep discount comes amid a quarter that saw elevated redemptions across most private-credit, non-traded BDCs.
Nvidia just hit an all-time high. Why some think a rally is just getting started
April 27, 2026
Shareholder returns are coming back into focus amid the semiconductor boom.
Jay Woods thinks worst may be over for software names if Microsoft gets above a key level this week
April 27, 2026
Jay Woods reviews key companies reporting earnings this week and touches on the most important takeaway from the upcoming FOMC meeting.

Stock Market

Stocks making the biggest moves after hours: LendingClub, Nucor, Rambus, Bed Bath & Beyond and more
April 27, 2026
See which stocks are posting big moves after the bell.
Investors usually 'sell in May and go away.' Why that may not work this year
April 27, 2026
The maxim may not hold up this year, as a stock market at all-time highs exhibits signs of further momentum.
Stocks making the biggest moves midday: Sandisk, Micron, Verizon, AMD, GE Vernova and more
April 27, 2026
These are the stocks posting the largest moves in midday trading.
Stocks making the biggest moves premarket: Qualcomm, Domino's Pizza, Adobe & more
April 27, 2026
These are the stocks posting the largest moves premarket.

Useful Resources & Links

Check the background of investment professionals on FINRA’s BrokerCheck.

Securities offered through Registered Representatives of Cambridge Investment Research, Inc., a broker-dealer, member FINRA/SIPC. Advisory services through Cambridge Investment Research Advisors, Inc., a Registered Investment Advisor. Cambridge and River City Financial are not affiliated. This communication is strictly intended for individuals residing in the states of AL, FL, KY, ME, NC, NJ, OH, SC, TX, VA, WA, WI and WV. No offers may be made or accepted from any resident outside the specific states referenced.

Cambridge’s Form CRS (Customer Relationship Summary)

The information being provided is strictly as a courtesy. When you link to any of these websites provided herein, River City Financial makes no representation as to the completeness or accuracy of information provided at these sites. Nor is the company liable for any direct or indirect technical or system issues or any consequences arising out of your access to or your use of third-party technologies, sites, information, and programs made available through this site.

River City Financial